GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00302583 | Colorectum | FAP | lipid modification | 52/2622 | 212/18723 | 2.84e-05 | 6.49e-04 | 52 |
GO:00302184 | Colorectum | FAP | erythrocyte differentiation | 34/2622 | 120/18723 | 3.13e-05 | 7.11e-04 | 34 |
GO:00300994 | Colorectum | FAP | myeloid cell differentiation | 81/2622 | 381/18723 | 6.33e-05 | 1.22e-03 | 81 |
GO:00018944 | Colorectum | FAP | tissue homeostasis | 61/2622 | 268/18723 | 6.71e-05 | 1.28e-03 | 61 |
GO:00602494 | Colorectum | FAP | anatomical structure homeostasis | 69/2622 | 314/18723 | 7.51e-05 | 1.37e-03 | 69 |
GO:00488724 | Colorectum | FAP | homeostasis of number of cells | 60/2622 | 272/18723 | 1.91e-04 | 2.79e-03 | 60 |
GO:00022624 | Colorectum | FAP | myeloid cell homeostasis | 39/2622 | 157/18723 | 2.03e-04 | 2.92e-03 | 39 |
GO:00075682 | Colorectum | FAP | aging | 69/2622 | 339/18723 | 7.66e-04 | 8.12e-03 | 69 |
GO:0008654 | Colorectum | FAP | phospholipid biosynthetic process | 54/2622 | 253/18723 | 8.88e-04 | 9.08e-03 | 54 |
GO:00066502 | Colorectum | FAP | glycerophospholipid metabolic process | 62/2622 | 306/18723 | 1.54e-03 | 1.38e-02 | 62 |
GO:00066442 | Colorectum | FAP | phospholipid metabolic process | 74/2622 | 383/18723 | 2.24e-03 | 1.83e-02 | 74 |
GO:00456463 | Colorectum | FAP | regulation of erythrocyte differentiation | 14/2622 | 47/18723 | 3.95e-03 | 2.75e-02 | 14 |
GO:0046474 | Colorectum | FAP | glycerophospholipid biosynthetic process | 44/2622 | 211/18723 | 3.98e-03 | 2.76e-02 | 44 |
GO:1903131 | Colorectum | FAP | mononuclear cell differentiation | 79/2622 | 426/18723 | 5.00e-03 | 3.33e-02 | 79 |
GO:19037063 | Colorectum | FAP | regulation of hemopoiesis | 69/2622 | 367/18723 | 6.01e-03 | 3.78e-02 | 69 |
GO:00450172 | Colorectum | FAP | glycerolipid biosynthetic process | 50/2622 | 252/18723 | 6.32e-03 | 3.95e-02 | 50 |
GO:00302244 | Colorectum | FAP | monocyte differentiation | 11/2622 | 36/18723 | 8.23e-03 | 4.82e-02 | 11 |
GO:00163114 | Colorectum | CRC | dephosphorylation | 79/2078 | 417/18723 | 1.27e-06 | 7.21e-05 | 79 |
GO:00341015 | Colorectum | CRC | erythrocyte homeostasis | 30/2078 | 129/18723 | 6.14e-05 | 1.35e-03 | 30 |
GO:00086541 | Colorectum | CRC | phospholipid biosynthetic process | 49/2078 | 253/18723 | 7.07e-05 | 1.51e-03 | 49 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04666 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
hsa046661 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
hsa046662 | Colorectum | SER | Fc gamma R-mediated phagocytosis | 39/1580 | 97/8465 | 5.84e-07 | 9.70e-06 | 7.04e-06 | 39 |
hsa046663 | Colorectum | SER | Fc gamma R-mediated phagocytosis | 39/1580 | 97/8465 | 5.84e-07 | 9.70e-06 | 7.04e-06 | 39 |
hsa046664 | Colorectum | MSS | Fc gamma R-mediated phagocytosis | 45/1875 | 97/8465 | 9.30e-08 | 1.56e-06 | 9.55e-07 | 45 |
hsa046665 | Colorectum | MSS | Fc gamma R-mediated phagocytosis | 45/1875 | 97/8465 | 9.30e-08 | 1.56e-06 | 9.55e-07 | 45 |
hsa046666 | Colorectum | FAP | Fc gamma R-mediated phagocytosis | 35/1404 | 97/8465 | 2.46e-06 | 4.28e-05 | 2.60e-05 | 35 |
hsa046667 | Colorectum | FAP | Fc gamma R-mediated phagocytosis | 35/1404 | 97/8465 | 2.46e-06 | 4.28e-05 | 2.60e-05 | 35 |
hsa046668 | Colorectum | CRC | Fc gamma R-mediated phagocytosis | 27/1091 | 97/8465 | 6.24e-05 | 1.12e-03 | 7.57e-04 | 27 |
hsa046669 | Colorectum | CRC | Fc gamma R-mediated phagocytosis | 27/1091 | 97/8465 | 6.24e-05 | 1.12e-03 | 7.57e-04 | 27 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
INPP5D | SNV | Missense_Mutation | novel | c.345N>A | p.Asp115Glu | p.D115E | Q92835 | protein_coding | tolerated(0.58) | benign(0.001) | TCGA-AO-A03V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
INPP5D | SNV | Missense_Mutation | rs758989076 | c.3170N>T | p.Ser1057Leu | p.S1057L | Q92835 | protein_coding | deleterious_low_confidence(0.05) | benign(0.003) | TCGA-AQ-A7U7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | rituximab | CR |
INPP5D | SNV | Missense_Mutation | | c.1606N>A | p.Gly536Arg | p.G536R | Q92835 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
INPP5D | SNV | Missense_Mutation | | c.2344N>A | p.Glu782Lys | p.E782K | Q92835 | protein_coding | tolerated(0.79) | benign(0.109) | TCGA-BH-A18F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
INPP5D | SNV | Missense_Mutation | rs781285468 | c.1934N>A | p.Arg645His | p.R645H | Q92835 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INPP5D | SNV | Missense_Mutation | novel | c.1730A>G | p.His577Arg | p.H577R | Q92835 | protein_coding | tolerated(0.84) | benign(0.286) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
INPP5D | SNV | Missense_Mutation | | c.1982C>T | p.Ala661Val | p.A661V | Q92835 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
INPP5D | SNV | Missense_Mutation | rs769891270 | c.3130C>T | p.Arg1044Trp | p.R1044W | Q92835 | protein_coding | deleterious(0) | possibly_damaging(0.865) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
INPP5D | SNV | Missense_Mutation | | c.3233N>C | p.Val1078Ala | p.V1078A | Q92835 | protein_coding | tolerated_low_confidence(0.45) | benign(0) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
INPP5D | SNV | Missense_Mutation | rs201032928 | c.3131G>A | p.Arg1044Gln | p.R1044Q | Q92835 | protein_coding | deleterious(0.03) | benign(0.267) | TCGA-C5-A7X3-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3635 | INPP5D | DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE | activator | 315661324 | ROSIPTOR | |
3635 | INPP5D | DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE | | TURNAGAINOLIDE B | TURNAGAINOLIDE B | 21539394 |
3635 | INPP5D | DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE | inhibitor | 336446950 | | |
3635 | INPP5D | DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE | | AQX-1125 | ROSIPTOR | |